Navigation Links
Generex Announces Investor Update Conference Call Planned for Late November
Date:10/24/2011

atform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whe
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Corporation (NYSE: CVS ) today announced that ... making a presentation to investors at the Citi Investment ... Mr. Merlo is scheduled to present at 2:10 pm ... webcast of the presentation will be broadcast simultaneously through ...
... NEW YORK, May 19, 2011 Two studies ... that an improved method for performing the standard upper endoscopy ... year increases the detection of pre-cancerous cells in the esophagus ... percent over the last 25 years, making it the fastest ...
Cached Medicine Technology:Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 2Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 3Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 4
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- Watching action shows ... study contends. People eat much more snack food while ... to the Cornell University researchers. "We find that if ... see more action too," study author Aner Tal, of the ... release. "In other words, the more distracting the program is, ...
(Date:9/1/2014)... 01, 2014 Currently, scientists continue ... treatments for Alzheimer's disease (AD), which reflects their ... regarding the diagnosis of the disease, especially in ... appropriate diagnostic tests. In 2014, after decades ... breakthroughs in the medicine world, there are still ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( ... litigation that continues to progress in the U.S. District ... , A federal Case List published on August ... cholesterol medication by plaintiffs who developed Type 2 diabetes ... Inc. failed to adequately warn patients and their doctors ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... who self-paid for their antiretroviral medications experienced interruptions ... or supply logistical disruptions. These treatment interruptions led ... in patients. ,These findings by a ... Institute at Makerere University, Kampala, and UCSF are ...
... 135-2 to pass (HB 1098) a Senate-approved bill that would ... until 2011, the New York Times reports.// ,Gov. ... that mandates that all girls entering the sixth grade beginning ... the executive order will allow parents who do not want ...
... least 3 years after undergoing in vitro fertilization (IVF) ... cell// research, according to a report. ,The ... of the report, was the complete and clear explanation ... legal advisor and embryologist, which helped couples navigate the ...
... Institute is seeking to raise glaucoma awareness among Mexican-Americans,// who ... Casa Grande Valley Dispatch reports. ,Mexican-Americans over ... family history of glaucoma all face a higher risk for ... the most common form glaucoma. ,The rate ...
... music and witty tales kept Delhi audiences enthralled as spiritual ... happiness and peace. ,Far from being a moral ... Thursday on 'Circus of the mind' was a simple talk ... is a very well-coordinated activity made to look like a ...
... The amount Americans spent on arthritis medications more than ... number of people// with the disease, increases in the ... inflation-adjusted cost per prescription, according to a new study ... a six-year study of U.S. arthritis patients and the ...
Cached Medicine News:Health News:Resistance to Anti-HIV Drugs in Uganda Developed Due to Drug Supply Problems 2Health News:Many Couples Choose to Donate Surplus Embryos for Stem Cell Research 2Health News:Mind Control is the Key to Happiness: Sadguru Jaggi Vasudev 2Health News:Treatment Cost for Arthritis on the Rise: Study 2
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
System, English (Continental cord), 230 VAC....
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Medicine Products: